New cholesterol drug tested in kidney patients
NCT ID NCT07322016
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how a new cholesterol-lowering tablet, HRS-1301, behaves in people with mild, moderate, or severe kidney problems compared to healthy volunteers. The goal is to understand if kidney function changes how the drug works, so doctors can give the right dose. About 36 adults aged 18 to 65 will take a single dose and be monitored closely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERLIPIDEMIAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sichuan Provincial People's Hospital
RECRUITINGChengdu, Sichuan, 610072, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- What does life feel like for children with a rare birth defect? a new study asks
- Fish oil pills put to the test: can they tame high triglycerides?
- Could a Two-Drug combo stop repeat heart attacks?
- Can cooking classes and exercise outperform medically tailored groceries for heart and kidney health?
- Kidney health may change how this drug works
- New cholesterol Drug's safety check: will it interfere with other meds?